A Lot-to-Lot Consistency Clinical Trial of PCV13

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
A Phase IIIb clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 to 5 years. The objective of the study is to evaluate the the Lot-to-Lot consistency, immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind phase IIIb clinical trial.
Epistemonikos ID: dc0054bd7abbee97c8a0ef43b332237977c20618
First added on: Sep 23, 2026